Wednesday, February 13, 2013
Lorus Therapeutics Inc., of Toronto, said that biomarker data for its lead cancer therapy, LOR-253, will be presented in April at the 2013 annual meeting of the American Association for Cancer Research in Washington.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.